vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and NexPoint Residential Trust, Inc. (NXRT). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $62.1M, roughly 1.0× NexPoint Residential Trust, Inc.). On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -2.7%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -4.1%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
NexPoint Residential Trust, Inc. is a publicly traded real estate investment trust focused on acquiring, renovating, and operating multifamily residential properties primarily across high-growth Sun Belt markets in the United States. Its portfolio consists mainly of affordable and mid-tier apartment communities, targeting steady rental income growth and long-term asset value appreciation for investors.
CTKB vs NXRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $62.1M |
| Net Profit | $-44.1M | — |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 8.4% |
| Net Margin | -70.9% | — |
| Revenue YoY | 8.1% | -2.7% |
| Net Profit YoY | -557.1% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $62.1M | ||
| Q3 25 | $52.3M | $62.8M | ||
| Q2 25 | $45.6M | $63.1M | ||
| Q1 25 | $41.5M | $63.2M | ||
| Q4 24 | $57.5M | $63.8M | ||
| Q3 24 | $51.5M | $64.1M | ||
| Q2 24 | $46.6M | $64.2M | ||
| Q1 24 | $44.9M | $67.6M |
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | $-7.8M | ||
| Q2 25 | $-5.6M | $-7.0M | ||
| Q1 25 | $-11.4M | $-6.9M | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | $-8.9M | ||
| Q2 24 | $-10.4M | $10.6M | ||
| Q1 24 | $-6.2M | $26.3M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 8.4% | ||
| Q3 25 | -17.6% | 11.8% | ||
| Q2 25 | -23.3% | 12.5% | ||
| Q1 25 | -36.1% | 11.7% | ||
| Q4 24 | 5.2% | 18.0% | ||
| Q3 24 | -8.2% | 8.7% | ||
| Q2 24 | -18.3% | 39.7% | ||
| Q1 24 | -23.9% | 60.7% |
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | -12.4% | ||
| Q2 25 | -12.2% | -11.1% | ||
| Q1 25 | -27.5% | -10.9% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | -13.8% | ||
| Q2 24 | -22.4% | 16.5% | ||
| Q1 24 | -13.8% | 38.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.31 | ||
| Q2 25 | — | $-0.28 | ||
| Q1 25 | — | $-0.27 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $0.40 | ||
| Q1 24 | — | $1.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $13.7M |
| Total DebtLower is stronger | — | $1.6B |
| Stockholders' EquityBook value | $341.7M | $295.5M |
| Total Assets | $461.5M | $1.9B |
| Debt / EquityLower = less leverage | — | 5.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $13.7M | ||
| Q3 25 | $93.3M | $10.8M | ||
| Q2 25 | $75.5M | $13.6M | ||
| Q1 25 | $95.3M | $23.7M | ||
| Q4 24 | $98.7M | $23.1M | ||
| Q3 24 | $162.3M | $17.4M | ||
| Q2 24 | $177.9M | $21.3M | ||
| Q1 24 | $168.8M | $37.2M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.5B |
| Q4 25 | $341.7M | $295.5M | ||
| Q3 25 | $378.6M | $322.9M | ||
| Q2 25 | $377.6M | $347.9M | ||
| Q1 25 | $379.6M | $379.9M | ||
| Q4 24 | $395.7M | $410.4M | ||
| Q3 24 | $385.5M | $447.1M | ||
| Q2 24 | $389.1M | $491.1M | ||
| Q1 24 | $392.6M | $512.8M |
| Q4 25 | $461.5M | $1.9B | ||
| Q3 25 | $494.9M | $1.8B | ||
| Q2 25 | $493.3M | $1.9B | ||
| Q1 25 | $482.6M | $1.9B | ||
| Q4 24 | $499.5M | $1.9B | ||
| Q3 24 | $491.2M | $2.0B | ||
| Q2 24 | $483.7M | $2.0B | ||
| Q1 24 | $492.1M | $2.0B |
| Q4 25 | — | 5.39× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.92× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $83.6M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $83.6M | ||
| Q3 25 | $-3.9M | $29.3M | ||
| Q2 25 | $108.0K | $19.9M | ||
| Q1 25 | $-125.0K | $28.3M | ||
| Q4 24 | $2.0M | $73.6M | ||
| Q3 24 | $13.2M | $27.8M | ||
| Q2 24 | $6.2M | $19.7M | ||
| Q1 24 | $4.0M | $19.7M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $3.4M | — |
| Q4 25 | -2.9% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 0.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
NXRT
Segment breakdown not available.
